Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Marcel O. Bonn-Miller is active.

Publication


Featured researches published by Marcel O. Bonn-Miller.


Experimental and Clinical Psychopharmacology | 2009

Relations Between Anxiety Sensitivity, Distress Tolerance, and Fear Reactivity to Bodily Sensations to Coping and Conformity Marijuana Use Motives Among Young Adult Marijuana Users

Michael J. Zvolensky; Erin C. Marshall; Kirsten A. Johnson; Julianna Hogan; Amit Bernstein; Marcel O. Bonn-Miller

The present investigation examines anxiety sensitivity, distress tolerance, and fear reactivity to bodily sensations in relation to Coping and Conformity marijuana use motives among a sample of young adult marijuana users (n = 135; 46.7% women; Mage = 20.45, SD = 5.0). After controlling for current marijuana use frequency (past 30 days), daily cigarette smoking rate, average volume of alcohol used over the past year, negative affectivity, and other marijuana use motives, anxiety sensitivity was significantly and uniquely associated with Coping and Conformity motives for marijuana use. Distress tolerance evidenced significant and unique incremental relations to Coping motives, whereas fear reactivity to bodily sensations was unrelated to any marijuana use motive. These results provide novel information related to the role of emotional sensitivity and tolerance factors as they pertain to specific types of motives for marijuana use among young adults.


American Journal on Addictions | 2009

An Evaluation of the Nature of Marijuana Use and Its Motives among Young Adult Active Users

Marcel O. Bonn-Miller; Michael J. Zvolensky

The present investigation examined marijuana use, abuse, and dependence in relation to self-reported marijuana use behaviors and motives, as well as concurrent cigarette and problematic alcohol use among a sample of young adult current marijuana users (n = 200; 44.5% women; M(age) = 21.48, SD = 6.54). Preliminary results broadly indicated that more severe forms of marijuana use (eg, dependence) were associated with a more problematic pattern of marijuana use behavior, polysubstance use, and greater motivation to use marijuana for multiple reasons. Results are discussed in relation to better understanding the underlying nature of marijuana use and its disorders among young adults.


Journal of Traumatic Stress | 2010

Multimethod study of distress tolerance and PTSD symptom severity in a trauma-exposed community sample.

Erin C. Marshall-Berenz; Anka A. Vujanovic; Marcel O. Bonn-Miller; Amit Bernstein; Michael J. Zvolensky

Despite initial evidence linking distress tolerance to posttraumatic stress disorder (PTSD) symptom severity, there is a need for the investigation of interrelations among multiple measures of distress tolerance and PTSD symptom severity. Therefore, the present study investigated concurrent relations among multiple measures of distress tolerance, as well as the relations between these measures and PTSD symptom severity, within a trauma-exposed community sample. The sample consisted of 81 trauma-exposed adults (63.1% women). Results indicated that Distress Tolerance Scale (Simons & Gaher, 2005) scores, but no other measures of distress tolerance were significantly related to PTSD symptom severity above and beyond the variance accounted for by number of traumas, trait-level neuroticism, and participant sex. Implications and future directions are discussed.


American Journal of Drug and Alcohol Abuse | 2014

Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users.

Marcel O. Bonn-Miller; Matthew Tyler Boden; Meggan M. Bucossi; Kimberly A. Babson

Abstract Objectives: Little research has investigated the demographic and symptom profile of medical cannabis users in states in the USA that have legalized cannabis use. Methods: In the present cross-sectional study, we investigated the demographic profile of 217 adults currently receiving medical cannabis, as well as differences in problematic use and perceived helpfulness in terms of (i) symptoms of psychological disorders and pain, and (ii) motives for use. Results: Findings indicated that medical cannabis users (i) use and perceive cannabis to be beneficial for multiple conditions, some for which cannabis is not specifically prescribed or allowed at the state level; and (ii) report similar rates of disordered use as compared with population estimates among regular users. Furthermore, problematic cannabis use was predicted by several symptoms of psychological disorders (e.g. depression) and a variety of use motives (e.g. coping), while cannabis was reported as particularly helpful among those with several psychological symptoms (e.g. traumatic intrusions), as well as those reporting use for social anxiety reasons. Conclusions: Results are discussed in terms of future directions for research given the current debates regarding legalization of cannabis for medical purposes and, more generally, the lack of empirical data to inform such debates.


Substance Use & Misuse | 2008

Emotional Dysregulation: Association With Coping-Oriented Marijuana Use Motives Among Current Marijuana Users

Marcel O. Bonn-Miller; Anka A. Vujanovic; Michael J. Zvolensky

The present investigation, conducted between 2005 and 2006, examined the relation between emotion dysregulation and motives for marijuana use among 136 (71 women; Mage = 20.61 years) young adult marijuana smokers. As expected, after covarying for theoretically relevant variables, the DERS–total score was significantly related to marijuana use coping motives, but no other motives for marijuana use. Further analysis indicated that the Non-acceptance of Emotional Responses subscale of the DERS accounted for the DERS-total score effect. Results are discussed in relation to better understanding the role of coping-motivated marijuana use within the context of an emotional dysregulation explanatory framework. Limitations of the study are noted.


JAMA | 2015

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products

Ryan Vandrey; Jeffrey C. Raber; Mark E. Raber; Brad Douglass; Cameron Miller; Marcel O. Bonn-Miller

Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16% to 26% of patients using medical cannabis consume edible products.1,2 Even though oral consumption lacks the harmful by-products of smoking, difficult dose titration can result in overdosing or underdosing, highlighting the importance of accurate product labeling. Regulation and quality assurance for edible product cannabinoid content and labeling are generally lacking. We investigated the label accuracy of edible cannabis products.


Psychology of Addictive Behaviors | 2011

Posttraumatic stress disorder and cannabis use in a nationally representative sample.

Jesse R. Cougle; Marcel O. Bonn-Miller; Anka A. Vujanovic; Michael J. Zvolensky; Kirsten A. Hawkins

The present study examined the relations between posttraumatic stress disorder (PTSD) and cannabis use in a large representative survey of adults (N = 5,672) from the United States (Kessler et al., 2004). After adjusting for sociodemographic variables (i.e., age, marital status, ethnicity, education, income, and sex), alcohol use disorders, and nicotine dependence, lifetime and current (past year) PTSD diagnoses were associated with increased odds of lifetime history of cannabis use as well as past year daily cannabis use. Lifetime, but not current, PTSD diagnosis also was uniquely associated with increased risk for any past year cannabis use. Additional analyses revealed that the relations between PTSD (lifetime and current) and lifetime cannabis use remained statistically significant when adjusting for co-occurring anxiety and mood disorders and trauma type frequency. Overall, these findings add to the emerging literature demonstrating a possibly important relationship between PTSD and cannabis use.


Cognitive Behaviour Therapy | 2004

Anxiety sensitivity: association with intensity of retrospectively‐rated smoking‐related withdrawal symptoms and motivation to quit

Michael J. Zvolensky; Kristin M. Baker; Ellen W. Leen-Feldner; Marcel O. Bonn-Miller; Matthew T. Feldner; Richard A. Brown

The present cross‐sectional study evaluated the associations between anxiety sensitivity, intensity of retrospectively‐rated nicotine withdrawal symptoms, and motivation to quit smoking. Participants were 127 young adult (mean age 20.4 years (SD 4.6)) regular smokers (mean cigarettes per day 10.2 (SD 5.1)). Anxiety sensitivity predicted intensity of retrospectively rated withdrawal symptoms during the first week of the most recent quit attempt as well as concurrent and lifetime indices of motivation to quit smoking even after controlling for theoretically‐relevant smoking (e.g. nicotine dependence) and affect (e.g. panic attack history) factors. These results are discussed in relation to better understanding panic‐related vulnerability factors in smoking cessation.


Cognitive Therapy and Research | 2004

Evaluating the Role of Anxiety Sensitivity in Smoking Outcome Expectancies Among Regular Smokers

Michael J. Zvolensky; Matthew T. Feldner; Ellen W. Leen-Feldner; Marcel O. Bonn-Miller; Alison C. McLeish; Kristin Gregor

The present study evaluated the association between the lower-order facets of anxiety sensitivity construct (physical, mental incapacitation, and social concerns) and positive (expectancies about negative affect reduction) and negative (expectancies about negative personal consequences) smoking outcome expectancies. Participants were 90 young adult regular smokers [37 females; Mage = 23.4 years (SD = 8.9); mean number of cigarettes/day = 11.7 (SD = 6.1)] with no history of psychopathology or nonclinical panic attacks recruited from the general population. Anxiety sensitivity physical concerns and mental incapacitation concerns, as indexed by the Anxiety Sensitivity Index (ASI; S. Reiss, R. A. Peterson, M. Gursky, & R. J. McNally, 1986), were significantly and incrementally associated with smoking outcome expectancies, as indexed by the Smoking Consequences Questionnaire (SCQ; T. H. Brandon & T. B. Baker, 1991), for negative affect reduction as well as negative personal consequences; the observed effects were over and above the variance accounted for by theoretically relevant smoking history characteristics, gender, and negative affectivity. Results are discussed in relation to better understanding motivational processes for smoking among groups at heightened risk for developing panic psychopathology.


Cognitive Behaviour Therapy | 2011

Posttraumatic Stress, Difficulties in Emotion Regulation, and Coping-Oriented Marijuana Use

Marcel O. Bonn-Miller; Anka A. Vujanovic; Matthew Tyler Boden; James J. Gross

In an effort to better understand factors that may explain prior findings of a positive relation between posttraumatic stress symptom severity and coping-oriented marijuana use motivation, the present study tested whether the association between posttraumatic stress symptom severity and marijuana use coping motives is mediated by difficulties in emotion regulation. Participants were 79 (39 women; M age = 22.29 years, SD = 6.99) community-recruited adults who reported (1) lifetime exposure to at least one posttraumatic stress disorder Criterion A traumatic event and (2) marijuana use in the past 30 days. Results indicated that difficulties in emotion regulation, as indexed by the Difficulties in Emotion Regulation Scale (Gratz & Roemer, 2004), fully mediated the association between posttraumatic stress symptom severity and marijuana use coping motives. Implications for the treatment of co-occurring posttraumatic stress and marijuana use are discussed.

Collaboration


Dive into the Marcel O. Bonn-Miller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kimberly A. Babson

VA Palo Alto Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Matthew Tyler Boden

VA Palo Alto Healthcare System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jodie A. Trafton

VA Palo Alto Healthcare System

View shared research outputs
Top Co-Authors

Avatar

Ryan Vandrey

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge